Clinical Trials Logo

Filter by:
NCT ID: NCT04732169 Withdrawn - Clinical trials for Treatment Resistant Depression

Cannabidiol for Treatment Resistant Depression

CBD
Start date: July 1, 2021
Phase: Phase 4
Study type: Interventional

With this study, the investigators will address the following scientific aims: 1. Demonstrate the antidepressant effects of CBD in human adults with treatment refractory MDD as measured by standard rating scales. 2. Confirm CBD's safety profile in human adult patients with MDD.

NCT ID: NCT04730076 Withdrawn - Clinical trials for Esophageal Stricture

Balloon Dilation Methods for Benign Esophageal Stricture

Start date: July 13, 2020
Phase: N/A
Study type: Interventional

This is the first head to head, prospective, randomized, double-blind clinical trial comparing two different approaches of balloon dilation (standard versus progressive dilation) for benign esophageal strictures. A retrospective study on patients with benign esophageal strictures that underwent balloon dilation using the proposed technique found considerable symptomatic improvement in dysphagia. The proposed balloon dilation method is a novel approach that will require fewer sessions of dilation and use fewer balloon dilation catheters to achieve a maximum balloon diameter of 18mm and result in a significant symptomatic improvement.

NCT ID: NCT04728698 Withdrawn - Covid19 Clinical Trials

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

Start date: March 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19 infection in hospitalized subjects with ARD/ARDS.

NCT ID: NCT04728646 Withdrawn - Clinical trials for Graft Vs Host Disease

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Start date: September 2021
Phase: Phase 4
Study type: Interventional

To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).

NCT ID: NCT04721990 Withdrawn - Hearing Loss Clinical Trials

Subjective and Objective Performance With the SONNET2EAS

Start date: April 2021
Phase: N/A
Study type: Interventional

Purpose: The purpose of this study is to demonstrate the non-inferiority and new features of an external speech processor for cochlear implant recipients. Participants: This study seeks to enroll 15 cochlear implant recipients listening to previous technology. Procedures (methods): Subjects will be programmed and tested with old and new technology.

NCT ID: NCT04721743 Withdrawn - Uveitis Clinical Trials

Microbiome as a ThErapeutic Response Biomarker

Start date: May 3, 2021
Phase:
Study type: Observational

Background: Uveitis is inflammation inside of the eye. It can cause vision loss. Little is known about the disease. There are few treatment options. Researchers want to learn how the bacteria in the gut might affect how people with uveitis respond to treatment. Objective: To investigate the natural bacteria present in the gut and intestines to study whether it might affect uveitis treatment. Eligibility: People ages 13 and older with non-infectious uveitis who are enrolled in the ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) trial, and their uveitis is being treated or will be treated with an oral corticosteroid, conventional immunosuppressive drugs, or adalimumab. Design: Participants will have 2 study visits at their respective clinical sites. The visits will be 6 months apart. The visits will align with the main ADVISE trial visits. Participants will give blood samples. A needle will be used to take blood from an arm vein. They will also give stool samples. They will get stool collection kits. They will collect each sample at home and send it to the NIH. Participants will complete online diet history questionnaires. They will get an ID and password to access the questionnaires. The ID is a unique code. This means it does not contain any personal identifiers. They can complete the questionnaires at home. Participation in this study will last for 6 months.

NCT ID: NCT04720274 Withdrawn - Hip Injuries Clinical Trials

Utilizing EMG Shorts in Hip Population

Start date: September 4, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to use a combination of electromyopathy (EMG) shorts and muscle monitoring software to collect data from participants performing physical exercises in order to determine the combination's diagnostic efficacy and ability to provide rehabilitative guidance for people who are recovering from hip injuries. Both healthy volunteers and Duke Patients seeking treatment for their hip pain and/or injuries will be enrolled in our research. If participants choose to take part they will be asked to wear these EMG shorts and perform various exercises like running on a treadmill, riding a stationary bike, or lifting weights. Participation in this study consists of one study visit for healthy volunteers, but will last up to six months for Duke Patients. At each standard of care clinic visit throughout six months, Duke Patients will be asked to also come in for a study visit, wear the EMG shorts, and perform the same exercises preformed during the first study visit.

NCT ID: NCT04719416 Withdrawn - Pediatric Cancer Clinical Trials

Relaxation Therapy in Pediatric Oncology

Start date: September 2022
Phase: N/A
Study type: Interventional

This study will look at the use of relaxation therapy in children with cancer. The study will compared patients who are current receiving treatment for their cancer and those who are currently in remission. Patients will be asked to listen to a short audio recording twice a week prior to going to bed which will walk patients through a mediation session. Surveys will be distributed through parental emails on the first of each month for each child to complete for the duration of 12 months. It is anticipated that the use of relaxation therapy will help to improve anxiety and pain levels in this population.

NCT ID: NCT04716959 Withdrawn - Clinical trials for Breast Reconstruction

Comparing Two Different Surgical Techniques for Breast Reconstruction

Start date: January 14, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare two standard techniques for breast reconstruction-the prepectoral technique and the subpectoral technique. Again, the prepectoral technique involves putting a tissue expander on top of the pectoralis muscle, while the subpectoral technique involves putting a tissue expander under the pectoralis muscle. The standard approach used at MSK is the subpectoral technique. This study will help researchers find out whether the subpectoral approach is better, the same as, or worse than the prepectoral approach. To decide which approach is better, the researchers will look at which technique causes fewer complications after surgery (for example, infection or the need for a second surgery). Researchers are also interested in seeing which approach causes less pain and use of pain medication after surgery.

NCT ID: NCT04713202 Withdrawn - Diarrhea Clinical Trials

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NET-PACS
Start date: March 3, 2021
Phase: Phase 2
Study type: Interventional

The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl. The main goal of the study is to demonstrate the feasibility of serial in-depth assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing treatment with PRRT using telotristat ethyl compared to placebo. We aim to report and describe from a patient's perspective the multi-faceted impact of carcinoid syndrome in patients with NETs and the changes on treatment while getting PRRT using telotristat ethyl compared to placebo.